Share This Page
Drug Price Trends for GNP LANSOPRAZOLE DR
✉ Email this page to a colleague
Average Pharmacy Cost for GNP LANSOPRAZOLE DR
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GNP LANSOPRAZOLE DR 15 MG CAP | 46122-0744-74 | 0.45940 | EACH | 2025-04-23 |
| GNP LANSOPRAZOLE DR 15 MG CAP | 46122-0744-04 | 0.45940 | EACH | 2025-04-23 |
| GNP LANSOPRAZOLE DR 15 MG CAP | 46122-0744-04 | 0.47401 | EACH | 2025-03-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Global Lansoprazole Market Analysis and Price Projections
Market Overview
Lansoprazole, a proton pump inhibitor (PPI), is widely used to treat various gastric disorders, including gastroesophageal reflux disease (GERD), duodenal and stomach ulcers, and NSAID-induced gastric ulcers. Here is a comprehensive analysis of the global lansoprazole market, including its current state, growth projections, and key factors influencing its trajectory.
Market Size and Growth Projections
The global lansoprazole market was valued at approximately US$ 1.89 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 5.8% from 2024 to 2030, reaching nearly US$ 2.81 billion by 2030[3].
Another estimate suggests that the market was worth US$ 362 million in 2023 and is forecasted to reach US$ 541.2 million by 2030, with a CAGR of 6.4% during the forecast period[5].
Key Drivers of the Market
Increasing Incidence of Gastric Diseases
The rise in incidence of GERD, gastric ulcers, duodenal ulcers, and other gastric diseases is a significant driver of the global lansoprazole market. According to the World Gastroenterology Organisation, the prevalence of GERD in North America ranges from 13.8% to 25.8%, which is significantly higher than in other regions[2][3].
Demand for Proton Pump Inhibitors
Proton pump inhibitors (PPIs) like lansoprazole are in high demand due to their effectiveness in treating gastric acid-related disorders. Ongoing clinical trials aimed at improving the efficiency of lansoprazole formulations also contribute to market growth[2][3].
Market Segmentation
Route of Administration
The global lansoprazole market is segmented based on the route of administration into oral and intravenous. The oral segment dominates the market due to the higher preference for capsule formulations among patients with mild to moderate GERD, the low cost of oral capsules, and the increased number of manufacturers offering lansoprazole in capsule forms[2][3].
Product Type
The market is segmented into capsules, OD tablets, and botulinum toxin. Capsules are the most prevalent form, but the botulinum toxin segment is expected to grow rapidly during the forecast period[3].
Distribution Channel
The market is divided into hospital pharmacies, online pharmacies, and retail pharmacies & drug stores. Retail pharmacies & drug stores dominate the market due to the ease of access and the availability of over-the-counter brands of lansoprazole[2].
Regional Analysis
North America
North America is expected to dominate the global lansoprazole market during the forecast period. This is attributed to the high incidence of GERD in the U.S. and a greater demand for sustained release proton pump inhibitor drugs in the region[2][3].
Other Regions
Other significant regions include Europe, Asia Pacific, Latin America, and the Middle East & Africa. Each region has its unique market dynamics, with Asia Pacific showing promising growth due to increasing healthcare expenditure and a rising prevalence of gastric diseases[1][3].
Competitive Landscape
Key players in the global lansoprazole market include Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Perrigo Company plc, Sun Pharmaceutical Industries Ltd., and several other pharmaceutical companies. These companies are involved in continuous research and development to improve lansoprazole formulations and expand their market presence[2][5].
Challenges and Restraints
New Drug Classes
The introduction of new drug classes such as H2 blockers and antacids, which offer immediate relief from GERD, is expected to restrain the growth of the lansoprazole market. Patient preference for these alternative treatments could reduce the demand for lansoprazole[2][3].
Price Projections
The pricing of lansoprazole is influenced by several factors, including the route of administration, product type, and distribution channel. Here are some key points regarding price projections:
- Oral Formulations: The cost of oral capsules is relatively low, which contributes to their high demand. The price is expected to remain competitive due to the presence of multiple manufacturers[2][3].
- Intravenous Formulations: These are typically more expensive than oral formulations but are used in more severe cases. The price is expected to stabilize as more generic versions become available[2].
- Regional Variations: Prices can vary significantly across different regions due to differences in healthcare policies, regulatory environments, and market competition[1][3].
Consumer Behavior and Preferences
Patients with mild to moderate GERD prefer oral capsule formulations due to their ease of use and lower cost. The convenience and accessibility of retail pharmacies also influence consumer behavior, making them a preferred distribution channel[2][3].
"According to the World Gastroenterology Organisation, in 2015, the prevalence of GERD ranged from 2.5% to 6.6% in Eastern Asia and 13.8% to 25.8% in North America"[2].
Technological and Clinical Trends
Ongoing clinical trials focused on improving the efficiency of lansoprazole formulations are expected to drive market growth. Additionally, advancements in drug delivery systems, such as sustained release formulations, are gaining traction and are likely to influence future market trends[2][3].
Key Takeaways
- The global lansoprazole market is driven by the increasing incidence of gastric diseases and the demand for proton pump inhibitors.
- The oral segment dominates the market due to patient preference and cost-effectiveness.
- North America is expected to be the leading region in the market due to high GERD prevalence.
- New drug classes and patient preferences for immediate relief treatments are potential restraints.
- Price projections indicate competitive pricing for oral formulations and regional variations in pricing.
Frequently Asked Questions (FAQs)
1. What is the expected market size of the global lansoprazole market by 2030?
The global lansoprazole market is expected to reach approximately US$ 2.81 billion by 2030[3].
2. What are the primary drivers of the global lansoprazole market?
The primary drivers include the increasing incidence of gastric diseases, demand for proton pump inhibitors, and ongoing clinical trials for new formulations[2][3].
3. Which segment dominates the global lansoprazole market in terms of route of administration?
The oral segment dominates the market due to higher patient preference and lower costs[2][3].
4. Who are the key players in the global lansoprazole market?
Key players include Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Perrigo Company plc, and Sun Pharmaceutical Industries Ltd.[2][5].
5. What are the potential restraints to the growth of the global lansoprazole market?
New drug classes such as H2 blockers and antacids, and patient preferences for immediate relief treatments, are potential restraints[2][3].
Cited Sources:
- Cognitive Market Research - Lansoprazole Market Report 2024 (Global Edition)[1]
- Biospace - Lansoprazole Market: The oral segment dominated the global market[2]
- Maximize Market Research - Lansoprazole Market: Global Industry Analysis and Forecast[3]
- MedOne - Drug Lookup | MedOne - Pharmacy Benefit Solutions[4]
- Valuates Reports - Lansoprazole - Market Size[5]
More… ↓
